HENDERSON, Nev. (TheStreet) --September sales of the Spectrum Pharmaceuticals' (SPPI) colon cancer drug Fusilev totaled $31.5 million in September, according to an estimate compiled by healthcare research firm Wolters Kluwer Wednesday.
For the three months that make up the third quarter, Fusilev estimated sales totaled $99 million. July sales were $31.8 million, August sales $35.4 million, according to Wolters Kluwer.
How accurately the Fusilev sales estimates track actual sales reported by Spectrum is a guessing game. In the second quarter, Spectrum reported Fusilev sales of $56.6 million, short of the $97 million suggested by the Wolters Kluwer monthly sales data.
Wolters Kluwer tracks gross sales of Fusilev while Spectrum reports net sales that subtract discounts, rebates and other financial incentives to doctors. As previously reported, Spectrum increased Fusilev discounting in the June quarter, which lowered the effective net selling price of Fusilev.If the same rough gross-to-net discounting trend continued in the third quarter, Spectrum could report slightly higher Fusilev sales of around $57 million. With so few analysts covering Spectrum, generating consensus estimates is difficult. Roth Capital Partners' Joe Pantginis lowered his third-quarter Fusilev sales estimate to $50.1 million from $58.2 million. RBC Capital's Adnan Butt is forecasting $59.4 million in Fusilev sales for the quarter. Fusilev sales comprised 86% of Spectrum's second-quarter revenue so how well the drug performs is vitally important to the company's future growth. Spectrum continues to benefit from supply shortages of leucovorin, a cheaper, generic equivalent to Fusilev. Spectrum shares were up 1% to $11.36 in early Wednesday trading. The stock is down 20% for the year despite a strong returns for the biotech sector, generally. -- Reported by Adam Feuerstein in Boston. Follow @AdamFeuerstein
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV